Jalota Deepika 4

What Happened Deepika Jalota, Chief Development Officer of PMV Pharmaceuticals (PMVP), was granted 303,310 derivative securities on March 5, 2026, reported on a Form 4 filed March 9, 2026. The award shows an acquisition price of $0.00 (code A), meaning no cash was paid for the grant; no immediate market sale or purchase occurred. The filing does not state a market value at grant.

Key Details

• Transaction date: 2026-03-05; Filing date: 2026-03-09 (timely — within the Form 4 two-business-day requirement).
• Amount: 303,310 derivative shares; reported price: $0.00 (award/grant).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: F1 — "Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026."
• Transaction code: A = Grant/Award (derivative security).

Context This was an equity compensation grant (derivative award) rather than a market purchase or sale. The award will vest monthly over four years beginning April 5, 2026; as the units vest they typically convert into actual shares (or become exercisable) per the company's award agreement. Such grants are common executive compensation and do not by themselves signal an immediate buy or sell decision by the insider.